MRD Status Impact on Secondary Acute Myeloid Leukemia Outcomes after Allogeneic Hematopoietic Cell Transplantation. A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Enrico Maffini(Istituto di Ematologia di Bologna), Arnon Nagler(Sheba Medical Center), Arnold Ganser(Medizinische Hochschule Hannover), Dietrich W. Beelen(Essen University Hospital), Mohamad Mohty(Sorbonne Université), Ben Carpenter(The Royal Free Hospital), Myriam Labopin(Sorbonne Université), Ibrahim Yakoub‐Agha(Inserm), Francesco Lanza(Istituti Ospitalieri di Cremona), Hans Martin(Goethe University Frankfurt), Nicolaus Kroeger, Rocío Parody Porras(Institut Català d'Oncologia), Jacques‐Olivier Bay(Centre Hospitalier Universitaire de Clermont-Ferrand), Keith Wilson(Cardiff University), Jakob Passweg(University Hospital of Basel), Eva Wagner(Johannes Gutenberg University Mainz), Mutlu Arat(Istanbul Florence Nightingale Hospital)
Transplantation and Cellular Therapy
January 30, 2021
10.1016/s2666-6367(21)00171-8
Cited by 0

Related Papers

Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
|Blood|1998|1.9k
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
|Blood|1998|1.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k